• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。

2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

出版信息

Korean J Radiol. 2019 Jul;20(7):1042-1113. doi: 10.3348/kjr.2019.0140.

DOI:10.3348/kjr.2019.0140
PMID:31270974
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6609431/
Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high in middle-aged and elderly patients. These practice guidelines will provide useful and constructive advice for the clinical management of patients with HCC. A total of 44 experts in hepatology, oncology, surgery, radiology, and radiation oncology in the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2014 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions.

摘要

肝细胞癌(HCC)是全球第五大常见癌症,在韩国也是男性中第四大常见癌症,在中年和老年患者中慢性乙型肝炎感染的患病率很高。这些临床实践指南将为 HCC 患者的临床管理提供有用和建设性的建议。韩国肝癌协会-韩国国家癌症中心实践指南修订委员会的 44 名肝病学、肿瘤学、外科学、放射学和放射肿瘤学专家对 2014 年韩国指南进行了修订,并制定了新的建议,这些建议整合了最新的研究结果和专家意见。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/7d5e97ef5604/kjr-20-1042-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/b4c6afcc1485/kjr-20-1042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/783af040fde4/kjr-20-1042-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/bf59e664fe04/kjr-20-1042-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/6422c152c5f7/kjr-20-1042-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/7d5e97ef5604/kjr-20-1042-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/b4c6afcc1485/kjr-20-1042-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/783af040fde4/kjr-20-1042-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/bf59e664fe04/kjr-20-1042-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/6422c152c5f7/kjr-20-1042-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf61/6609431/7d5e97ef5604/kjr-20-1042-g005.jpg

相似文献

1
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Korean J Radiol. 2019 Jul;20(7):1042-1113. doi: 10.3348/kjr.2019.0140.
2
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
3
2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2018 韩国肝癌协会-韩国国家癌症中心肝细胞癌管理实践指南。
Gut Liver. 2019 May 15;13(3):227-299. doi: 10.5009/gnl19024.
4
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.2022KLCA-NCC 韩国肝细胞癌管理实践指南。
Korean J Radiol. 2022 Dec;23(12):1126-1240. doi: 10.3348/kjr.2022.0822.
5
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.《2022年韩国肝脏癌协会-韩国国立癌症中心肝细胞癌管理实践指南》
J Liver Cancer. 2023 Mar;23(1):1-120. doi: 10.17998/jlc.2022.11.07. Epub 2022 Dec 9.
6
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.肝细胞癌的临床实践指南与实际临床实践:韩国视角。
Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5.
7
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.2014年韩国肝癌研究组-韩国国立癌症中心肝细胞癌管理实践指南
Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13.
8
Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues.肝细胞癌的非侵入性诊断:韩国肝癌研究组-韩国国立癌症中心实践指南与其他指南的对比及遗留问题阐述
Korean J Radiol. 2016 Jan-Feb;17(1):7-24. doi: 10.3348/kjr.2016.17.1.7. Epub 2016 Jan 6.
9
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.2014年韩国肝脏研究学会-国立癌症中心肝细胞癌管理韩国实践指南
Gut Liver. 2015 May 23;9(3):267-317. doi: 10.5009/gnl14460.
10
[Practice guidelines for management of hepatocellular carcinoma 2009].《2009年肝细胞癌管理实践指南》
Korean J Hepatol. 2009 Sep;15(3):391-423. doi: 10.3350/kjhep.2009.15.3.391.

引用本文的文献

1
The effect of continuous infusion chemotherapy through femoral artery catheterization on GP73, AFP-L3, and safety efficacy in liver cancer patients.经股动脉插管持续输注化疗对肝癌患者GP73、甲胎蛋白异质体L3及安全性疗效的影响
Clin Exp Med. 2025 May 10;25(1):148. doi: 10.1007/s10238-025-01560-y.
2
Vision transformer-based model can optimize curative-intent treatment for patients with recurrent hepatocellular carcinoma.基于视觉变换器的模型可以优化复发性肝细胞癌患者的根治性治疗。
Nat Commun. 2025 May 1;16(1):4081. doi: 10.1038/s41467-025-59197-0.
3
Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome.

本文引用的文献

1
Statins and metformin for chemoprevention of hepatocellular carcinoma.他汀类药物和二甲双胍用于肝细胞癌的化学预防
Clin Liver Dis (Hoboken). 2016 Aug 29;8(2):48-52. doi: 10.1002/cld.568. eCollection 2016 Aug.
2
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab(REACH-2):一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
3
病例报告:信迪利单抗诱导的吉兰-巴雷综合征后成功再次使用免疫检查点抑制剂
Front Immunol. 2025 Mar 19;16:1546886. doi: 10.3389/fimmu.2025.1546886. eCollection 2025.
4
Enhanced radiofrequency ablation for recurrent hepatocellular carcinoma post-transarterial chemoembolization: a prospective study utilizing twin internally cooled-perfusion electrodes.经动脉化疗栓塞术后复发性肝细胞癌的增强射频消融:一项使用双内部冷却灌注电极的前瞻性研究。
J Liver Cancer. 2025 Mar;25(1):91-98. doi: 10.17998/jlc.2025.01.25. Epub 2025 Feb 7.
5
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification.脂肪性肝病所致肝细胞癌的风险及其新提出的亚分类
Liver Cancer. 2024 Mar 12;13(5):561-571. doi: 10.1159/000538301. eCollection 2024 Oct.
6
Role of Imaging in Screening for Hepatocellular Carcinoma.影像学在肝细胞癌筛查中的作用。
Cancers (Basel). 2024 Oct 5;16(19):3400. doi: 10.3390/cancers16193400.
7
Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C-related Hepatocellular Carcinoma Among Egyptians: A Prospective Study.血清细胞角蛋白片段21-1和细胞角蛋白19-2G2作为埃及丙型肝炎相关肝细胞癌经动脉化疗栓塞反应的预测生物标志物:一项前瞻性研究。
J Clin Exp Hepatol. 2025 Jan-Feb;15(1):102405. doi: 10.1016/j.jceh.2024.102405. Epub 2024 Aug 17.
8
Prospective Study of Non-Contrast, Abbreviated MRI for Hepatocellular Carcinoma Surveillance in Patients with Suboptimal Hepatic Visualisation on Ultrasound.针对超声检查肝脏显影不佳的患者,采用非增强简化磁共振成像进行肝细胞癌监测的前瞻性研究。
Cancers (Basel). 2024 Jul 30;16(15):2709. doi: 10.3390/cancers16152709.
9
Clinical guidelines for early hepatocellular carcinoma treatment options: a systematic review and bibliometric analysis.早期肝细胞癌治疗选择的临床指南:系统评价与文献计量分析
Int J Surg. 2024 Nov 1;110(11):7234-7244. doi: 10.1097/JS9.0000000000001950.
10
Liver Resection Criteria for Patients with Hepatocellular Carcinoma and Multiple Tumors Based on Total Tumor Volume.基于肿瘤总体积的肝癌多结节患者肝切除术标准。
Dig Dis Sci. 2024 Aug;69(8):3069-3078. doi: 10.1007/s10620-024-08500-y. Epub 2024 Jun 1.
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
索拉非尼联合或不联合经动脉化疗栓塞治疗晚期肝细胞癌患者的 III 期 STAH 试验。
J Hepatol. 2019 Apr;70(4):684-691. doi: 10.1016/j.jhep.2018.11.029. Epub 2018 Dec 6.
4
Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.细胞因子诱导的杀伤细胞辅助免疫治疗肝癌的长期疗效:5 年随访延长。
Cancer Immunol Immunother. 2019 Jan;68(1):23-32. doi: 10.1007/s00262-018-2247-4. Epub 2018 Sep 19.
5
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
6
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.替沃扎尼布用于 MET 高表达、晚期肝细胞癌的二线治疗(METIV-HCC):一项 III 期、随机、安慰剂对照研究的最终分析。
Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.
7
Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.经动脉化疗栓塞联合外照射放疗与索拉非尼治疗伴有宏观血管侵犯的肝细胞癌的疗效和安全性:一项随机临床试验。
JAMA Oncol. 2018 May 1;4(5):661-669. doi: 10.1001/jamaoncol.2017.5847.
8
A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma.一项比较射频消融与肝切除术治疗肝细胞癌的前瞻性随机研究。
Ann Surg Treat Res. 2018 Feb;94(2):74-82. doi: 10.4174/astr.2018.94.2.74. Epub 2018 Jan 30.
9
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较:一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
10
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis.肝硬化患者肝细胞癌早期检测的监测成像和甲胎蛋白:一项荟萃分析。
Gastroenterology. 2018 May;154(6):1706-1718.e1. doi: 10.1053/j.gastro.2018.01.064. Epub 2018 Feb 6.